5-6 February 2021 Virtual Conference
![]() |
![]() |
![]() |
![]() |
P-001 | Surgery versus Sorafenib in case of BCLC-C hepatocellular carcinoma: an Italian weighted study | Simone Famularo | ![]() |
![]() |
|||
P-002 | Current Trends of Hepatocellular Carcinoma Characteristics in Greece | Georgios Markakis | ![]() |
![]() |
|||
P-004 | Association between serum magnesium concentration and hepatocellular carcinoma in cirrhotic patients | Simona Parisse | ![]() |
![]() |
|||
P-005 | The best potential treatment for recurrent hepatocellular carcinoma after surgery: a machine learning predictive model for treatment allocation based on an Italian multicentric database | Francesca Carissimi | ![]() |
![]() |
|||
P-009 | Hepatocellular carcinoma prognostic scores: filling the gap? | Michele Campigotto | ![]() |
![]() |
|||
P-011 | Increased platelet aggregation in patients with cirrhosis and hepatocellular carcinoma: a new potential therapeutic target? | Alberto Zanetto | ![]() |
![]() |
|||
P-013 | chronic hepatitis b under tenofovir or entecavir: performance of the page-b score to predict hepatocellular carcinoma | Daniela Falcão | ![]() |
![]() |
|||
P-014 | Diagnosing hepatocellular carcinoma are we getting it right first time? | Emma Saunsbury | ![]() |
![]() |
|||
P-018 | Association between postoperative early recurrence of hepatocellular carcinoma and the expression pattern of circulating tumor cells in peripheral blood sample: a preliminary study. | Cristina Ciulli | ![]() |
![]() |
|||
P-019 | Circulating prostaglandin E2: a novel potential prognostic biomarker in patients with hepatocellular carcinoma | Filippo Pelizzaro | ![]() |
![]() |
|||
P-021 | Prognostic role of platelets-to lymphocytes ratio (PLR) and neutrophils-to-lymphocytes ratio (NLR) in hepatocellular carcinoma patients | Filippo Pelizzaro | ![]() |
![]() |
|||
P-022 | Impact of hospital volume on hepatocellular carcinoma survival in Italy | Filippo Pelizzaro | ![]() |
![]() |
|||
P-025 | Radiofrequency ablation versus surgical resection for the treatment of solitary hepatocellular carcinoma 2cm or smaller: a cohort study in Taiwan | Ching-Sheng Hsu | ![]() |
![]() |
|||
P-027 | Phenotypic characteristics of the tumour microenvironment in primary and secondary hepatocellular carcinoma. | Petros Fessas | ![]() |
![]() |
|||
P-028 | Are undetected stones in the common biliary duct one of the causes of abscesses and bilomas development after percutaneous thermal ablation procedures? | Letizia Veronese | ![]() |
![]() |
|||
P-029 | Different modalities in management of bleeding related to post-banding ulcer following endoscopic variceal ligation in cirrhotic patients with or without hepatocellular Carcinoma | Mohamed Abdel-Samiee | ![]() |
![]() |
|||
P-032 | NADPH oxidase 4 (Nox4) deletion accelerates liver regeneration in mice | MACARENA HERRANZ ITÚRBIDE | ![]() |
![]() |
|||
P-034 | Methylated Septin 9 (mSEPT9) as a biomarker for hepatocellular carcinoma. Results from University Hospital Coventry and Warwickshire NHS Trust, UK | Ayman Bannaga | ![]() |
![]() |
|||
P-036 | Trans-arterial chemoembolization as a loco-regional inducer of immunogenic cell death in hepatocellular carcinoma: implications for immunotherapy. | David Pinato | ![]() |
![]() |
|||
P-037 | PNPLA3 and Notch3 gene polymorphisms as risk factors for alcoholic cirrhosis development and its progression to hepatocellular carcinoma | Anna Mrzljak | ![]() |
![]() |
|||
P-038 | Urinary volatile organic compounds characterization in hepatocellular carcinoma pilot study | Ayman Bannaga | ![]() |
![]() |
|||
P-039 | Comparison of incidence and mortality risks due to acute kidney injury in hepatocellular carcinoma patients after liver resection, ablation, and transarterial chemoembolization: Meta-analysis of cohort studies | Boby Pratama Putra | ![]() |
![]() |
|||
P-041 | Transarterial chemoembolization: Predictors of liver function deterioration prior to hepatocellular carcinoma refractoriness | Joel Ferreira-Silva | ![]() |
![]() |
|||
P-042 | Two birds one stone: a case of synchronous hepatocellular carcinoma and intrahepatic cholangiocarcinoma | Catarina Félix | ![]() |
![]() |
|||
P-048 | Balloon occluded TACE (B-TACE) vs DEM-TACE for HCC. A single center retrospective case control study. | Bianca Rocco | ![]() |
![]() |
|||
P-049 | Perfusion analysis with dynamic contrast enhanced ultrasound for the diagnosis of hepatocellular carcinoma: a pilot study of a novel parameter aiming to improve the detection of wash-out | Lorenzo Mulazzani | ![]() |
![]() |
|||
P-054 | Evaluation of cardiovascular events in patients with hepatocellular carcinoma treated with sorafenib in the clinical practice: CARDIO-SOR study. | Lorena Carballo-Folgoso | ![]() |
![]() |
|||
P-055 | Treatment of the chemotherapy induced hepatotoxicity | Mariia Zharova | ![]() |
![]() |
|||
P-057 | Hepatocellular Carcinoma Surveillance in Cirrhotic patients. | Shreyashee Sengupta | ![]() |
![]() |
|||
P-059 | Targeting tumor-initiating cells and compensatory YAP pathway activation to overcome sorafenib-induced resistance in hepatocellular carcinoma | Darko Castven | ![]() |
![]() |
|||
P-060 | Immunosuppressive Drug Resistant Armored TCR T cells for immune-therapy of HCC in liver transplant patients | Anthony Tan | ![]() |
![]() |
|||
P-062 | The impact of ultrasonographic blind spots for detecting early-stage hepatocellular carcinoma during surveillance | HA IL KIM | ![]() |
![]() |
|||
P-066 | The combination of alcohol and metabolic syndrome is a fast track to hepatic tumorigenesis | Raquel Benedé-Ubieto | ![]() |
![]() |
|||
P-067 | Thyroid disease and hepatocellular carcinoma survival. A Danish nationwide cohort study | Linda Skibsted Kornerup | ![]() |
![]() |
|||
P-068 | Usefulness of circulating tumor cells in the management of patients with hepatocellular carcinoma | Elena Vargas Accarino | ![]() |
![]() |
|||
P-069 | Prognostic value of metabolic imaging data of C-choline PET/CT in patients undergoing hepatectomy for hepatocellular carcinoma | Jacopo Galvanin | ![]() |
![]() |
|||
P-071 | Extracellular signal-regulated kinase 5 regulates the malignant phenotype of cholangiocarcinoma cells | Alessandra Gentilini | ![]() |
![]() |
|||
P-075 | Tumor Burden Score: a novel tool to predict immune-related liver injury during immunotherapy for hepatocellular carcinoma | Antonio DAlessio | ![]() |
![]() |
|||
P-076 | Phase 3 KEYNOTE-937 Trial: Adjuvant Pembrolizumab for Hepatocellular Carcinoma and Complete Radiologic Response After Surgical Resection or Local Ablation | Arndt Vogel | ![]() |
![]() |
|||
P-077 | PRPF8 regulates FAK/AKT pathway via fibronectin 1 splicing modulation to promote hepatocellular carcinoma aggressiveness | Juan Luis López-Cánovas | ![]() |
![]() |
|||
P-078 | Retrospective analysis of one-center experience in diagnosis and treatment of liver cancer | Mariia Zharova | ![]() |
![]() |
|||
P-079 | Analysis of risk factors associated with hepatocellular carcinoma development in patients with hepatitis B virus infection | Christos Triantos | ![]() |
![]() |
|||
P-081 | Validation of the aMAP risk score for the development of hepatocellular cancer in patients with cirrhosis in Glasgow | Chris Curran | ![]() |
![]() |
|||
P-082 | In vivo quantification of micro-balloon interventions (MBI) advantage. Cohort, retrospective, bi-centric study of DEB-TACE vs b-TACE and SIRT vs b-SIRT | Claudio Trobiani | ![]() |
![]() |
|||
P-083 | Comparison of Liver Transplant Criteria for Hepatocellular Carcinoma | Volkan &304;nce | ![]() |
![]() |
|||
P-085 | DNA Methyltransferases as Potential Biomarkers for Egyptian Patients with HCV Related Hepatocellular Carcinoma | Mohamed Abdel-Samiee | ![]() |
![]() |
|||
P-086 | Survival analysis of the most frequent Single Nucleotide Variants in Hepatocellular Carcinoma | Jimmy A. Daza Barragan | ![]() |
![]() |
|||
P-087 | Se and Zn supplements attenuates HCC among recovered Hepatitis C Obese population in Middle Belt Nigeria. | OLAJUYIN OLALEYE | ![]() |
![]() |
|||
P-088 | CAMD score predicts the risk of hepatocellular carcinoma in Tunisian patients with chronic hepatitis B on antiviral therapy | Myriam Ayari | ![]() |
![]() |
|||
P-091 | Real-world experience of hepatocellular carcinoma patients after sorafenib treatment: eligibility to subsequent lines and prognostic factors. | Leonardo Gomes da Fonseca | ![]() |
![]() |
|||
P-094 | Pattern of macrovascular invasion in patients with hepatocellular carcinoma influences treatment and outcome. | Maria Guarino | ![]() |
![]() |
|||
P-098 | Prediction of early recurrence of hepatocellular carcinoma after resection: international validation of the ERASL risk models | Berend Beumer | ![]() |
![]() |
|||
P-101 | Is first- and second-line immunotherapy sequence the optimal strategy for unresectable hepatocellular carcinoma? | Ciro Celsa | ![]() |
![]() |
|||
P-102 | Circulating miR 373 but not miR 210 as a new promising preoperative predictor of response to superive transarterial chemoembolization bridging therapy in Egyptian patients with hepatocellular carcinoma on top of hepatitis C virus infection | Omneya AbdelKarem | ![]() |
![]() |
|||
P-103 | Systematic review and meta-analysis of validated prognostic models for resected hepatocellular carcinoma patients | Berend Beumer | ![]() |
![]() |
|||
P-107 | lncRNA-H19 as a marker of liver disease progression: Hepatocellular Carcinoma | Ángela Rojas | ![]() |
![]() |
|||
P-110 | Epidemiological trends of hepatocellular carcinoma in patients with Metabolic-Dysfunction-Associated Fatty Liver Disease (MAFLD) in Italy. | Monica Cucco | ![]() |
![]() |
|||
P-112 | Are Radiology-based endpoints robust surrogate outcomes of overall survival in hepatocellular carcinoma patients treated with transarterial chemoembolization? | Ciro Celsa | ![]() |
![]() |
|||
P-113 | Vimentin expression in hepatocellular carcinoma relates with progenitor cells and epithelial-mesenchymal transition carcinogenesis | Joana Espírito Santo | ![]() |
![]() |
|||
P-119 | Modified Page B Score Performance in Predicting HCC Risk in patients with chronic hepatitis B on antiviral therapy. | Fatma Ben Farhat | ![]() |
![]() |
|||
P-122 | Prognostic performance of Toronto HCC risk index and the alpha-fetoprotein rate in patients with Hepatocellular carcinoma | Nouha Trad | ![]() |
![]() |
|||
P-125 | Performance of ten non-invasive liver function tests in predicting one-year mortality in patients with hepatocellular carcinoma | Nouha Trad | ![]() |
![]() |
|||
P-126 | Impact of Hepatocellular Carcinoma screening in patients with Non-Achoholic Fatty Liver Disease and survival analyzis: a Brazilian Cross-Section Study | Regiane Saraiva de Souza Melo Alencar | ![]() |
![]() |
5-6 February 2021 Virtual Conference
![]() |
Digital Object Identifier. Official code used to identify documents published on internet; similar to ISBN for books. You may use this code to reference your poster in future scientific publications or CVs. It can be found from anywhere in the world. ![]() To find the poster page, log onto www.medra.org and enter the DOI, or enter in your internet browser https://dx.doi.org/ followed by the DOI string asigned to your congress. ![]() |
![]() |
||
![]() |
|